The Canadian province of Ontario is limiting patient access to Takeda’s controversial diabetes medication Actos (generic: pioglitazone) due to the risk of bladder cancer that has become increasingly linked to the drug. The Ontario Public Drug (OPD) program has announced that it is removing Actos from its list of approved drugs, which means that in the future patients will need to go through special steps in order to obtain the medication. Signs and symptoms of Actos-induced bladder cancer may include blood or blood clots in the urine, pain during urination (dysuria), urinating small amounts frequently, and frequent urinary tract infections.
Actos Bladder Cancer Lawsuit Update April 8, 2014: In the first U.S. trial of its kind, Takeda Pharmaceuticals and Eli Lilly were ordered to pay a total of $9 billion in punitive damages after a jury agreed that the companies failed to warn the public and medical communities about the bladder cancer risk associated with their controversial type 2 diabetes drug Actos (pioglitazone). The lawsuit claimed that Takeda and Lilly downplayed or ignored concerns about Actos’ link to bladder cancer, and mislead health authorities in order to protect profits. Click here to learn more.
Free Actos Bladder Cancer Lawsuit Evaluation: If you or a loved one has been diagnosed with bladder cancer after taking Actos, you should contact our law firm immediately. You may be entitled to compensation by filing a suit against the manufacturer of Actos and we can help.
What’s the problem?
April 26, 2012 – The new OPD action comes just days after Health Canada issued a press release announcing an Actos bladder cancer warning, stating that the longer a patient takes the drug and the higher the dose received, the greater the likelihood of contracting the disease.
As a result, Actos has been added to the OPD’s Exceptional Access Program (EAP), which means that doctors will no longer be able to prescribe the drug at will. Instead, diabetes patients seeking Actos will have to submit a formal written request for the drug, explaining why use is necessary. The new procedures went into effect on Tuesday.
Manufactured and marketed by Takeda Pharmaceuticals, Actos is an FDA-approved once-a-day pill that is designed to increase the body’s sensitivity to insulin. The drug has been widely prescribed over the past several years, generating an astronomical $4.3 billion in sales for Takeda in 2011 alone.
Reports of bladder cancer among Actos users have prompted updated warning labels in the U.S. and Europe, and an Actos recall was issued last summer in France after studies found an increased risk of the disease in patients being treated with the drug.
Here at home in the United States, a growing number of Actos bladder cancer lawsuits have been filed in courthouses around the country on behalf of individuals who allegedly developed the disease while taking the drug. All the claims involve similar allegations that Takeda failed to provide adequate warnings to the public about the serious health risks associated with its best-selling diabetes medication.
The U.S. federal Actos litigation has been consolidated for pretrial proceedings as part of a multidistrict litigation (MDL), which is currently centralized in the U.S. District Court for the Western District of Louisiana.
Do You Have an Actos Bladder Cancer Lawsuit?
The Product Liability & Defective Drug Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Actos lawsuits. We are handling individual litigation nationwide and currently accepting new bladder cancer cases in all 50 states.
Free Actos Bladder Cancer Lawsuit Evaluation: If you or a loved one has been diagnosed with bladder cancer after taking Actos, you should contact our law firm immediately. You may be entitled to compensation by filing an Actos bladder cancer suit and we can help.